John Vavricka - Jan 31, 2022 Form 4 Insider Report for Atea Pharmaceuticals, Inc. (AVIR)

Role
Chief Commercial Officer
Signature
/s/ Andrea Corcoran, as Attorney-in-Fact for John Vavricka, Andrea Corcoran, as Attorney-in-Fact for John Vavricka
Stock symbol
AVIR
Transactions as of
Jan 31, 2022
Transactions value $
$0
Form type
4
Date filed
2/2/2022, 04:15 PM
Next filing
Feb 2, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AVIR Stock Option (Right to Buy) Award $0 +135K $0.00 135K Jan 31, 2022 Common Stock 135K $7.14 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option vests and becomes exercisable in forty-eight (48) equal monthly installments following January 31, 2022.